What are the differences between Trellegy (fluticasone furoate/umeclidinium/vilanterol) and Breztri (beclomethasone dipropionate/formoterol/glycopyrrolate) for COPD treatment?

Trellegy vs Breztri for COPD Treatment

For most COPD patients requiring triple therapy, Trellegy (fluticasone furoate/umeclidinium/vilanterol) appears to be the preferred initial choice over Breztri (budesonide/glycopyrrolate/formoterol), based on the most recent and highest-quality real-world evidence showing lower exacerbation rates and mortality risk. 1

Key Evidence Supporting Trellegy

The most recent 2025 Medicare comparative effectiveness study of 44,542 patients demonstrated that Trellegy users had 12% lower annualized moderate-severe exacerbation rates (0.80 vs 0.91 per patient-year; RR 0.88, p<0.001) and 11% lower all-cause mortality at 12 months (5.6% vs 6.4%; HR 0.89, p=0.020) compared to Breztri 1. This represents the strongest evidence prioritizing morbidity and mortality outcomes.

A 2026 Taiwanese population-based study of 12,971 patients corroborated these findings, showing Trellegy reduced:

• Severe exacerbations by 20% (HR 0.80)
• Moderate exacerbations by 20% (HR 0.80)
• Pneumonia risk marginally (HR 0.85, though not statistically significant) 2

Important Nuance: Treatment Duration Matters

However, among patients who maintain therapy ≥90 days (approximately 73% of initiators), the differences between Trellegy and Breztri become minimal 2. In this adherent subgroup:

• Severe exacerbations: HR 0.98 (no significant difference)
• Pneumonia: HR 0.93 (no significant difference)
• Cardiovascular events: HR 1.07 (no significant difference)
• Moderate exacerbations: HR 0.86 (Trellegy still slightly better)

This suggests Trellegy's advantage is most pronounced during treatment initiation and early months, making it the optimal first choice, but both medications perform comparably in patients who tolerate and continue therapy long-term.

Contradictory Evidence to Consider

One 2026 retrospective cohort study found opposite results, reporting Breztri had lower exacerbation rates (3.9% vs 5.6%; RR 1.44 for Trellegy) and acute respiratory failure (1.9% vs 2.5%; RR 1.28 for Trellegy) 3. However, this study is outweighed by the larger 2025 Medicare study 1 which had:

• Larger sample size (44,542 vs smaller cohort)
• More robust propensity score methodology
• Consistent findings with the 2026 Taiwanese study 2

Guideline Context

The 2023 Canadian Thoracic Society guidelines recommend single-inhaler triple therapy (SITT) preferentially over multiple inhalers for symptomatic COPD patients at high exacerbation risk (≥2 moderate or ≥1 severe exacerbation annually) 4. Both Trellegy and Breztri qualify as SITT options, but the guidelines don't specify preference between specific formulations.

Practical Considerations

Device and Dosing Differences:

• Trellegy: Once-daily dry powder inhaler (ELLIPTA device) 5
• Breztri: Twice-daily metered dose inhaler

The once-daily dosing of Trellegy may improve adherence, which is critical since adherence correlates with better outcomes 6.

Clinical Algorithm for Selection

1. First-line choice: Initiate Trellegy for most COPD patients requiring triple therapy based on superior early exacerbation reduction and mortality benefit
2. Consider Breztri if:
   • Patient cannot use dry powder inhalers effectively (poor inspiratory flow)
   • Patient specifically prefers metered dose inhalers
   • Cost/insurance coverage strongly favors Breztri
3. Monitor closely during first 90 days: This is when Trellegy shows greatest advantage
4. If patient tolerates and continues therapy >90 days: Both medications demonstrate comparable long-term effectiveness

Safety Profile

Both medications share similar safety concerns typical of ICS/LABA/LAMA combinations 5:

• Pneumonia risk (monitor for signs/symptoms)
• Cardiovascular effects from beta-agonist stimulation
• Glaucoma/cataracts with long-term ICS use
• Urinary retention from anticholinergic component
• Adrenal suppression with high-dose ICS

Cardiovascular events showed no significant difference between medications 2, 1.

Common Pitfalls to Avoid

• Don't delay triple therapy escalation in patients with ≥2 moderate or ≥1 severe exacerbations on dual therapy 4
• Don't use for acute symptom relief - both are maintenance therapies only 5
• Don't combine with additional LABA-containing medications - risk of overdose 5
• Don't assume all triple therapies are equivalent - real-world data shows meaningful differences in outcomes 1